



Dr. Martin Jäger

Dr. Martin Jäger is Counsel at Hausfeld in Düsseldorf with a focus on competition litigation, merger control and distribution antitrust law with many years of diverse expertise, in particular in areas related to IP and in cartel damage cases, as well as with a particular focus in advising clients from the healthcare industry.

Prior to joining Hausfeld, Martin was Senior Counsel at a leading German law firm in Düsseldorf and previously worked in another law firm in Frankfurt am Main, Düsseldorf, Brussels and London. Having studied in Heidelberg and Geneva, Martin holds a Ph.D. He is the author of the bi-monthly media antitrust law column for the "Archiv für Presserecht" (AfP).

Martin Jäger is fluent in German, English and has good knowledge of French.



DÜSSELDORF



+49 211 4187 3330



martin.jaeger@hausfeld.com

PRACTICE AREAS

Competition Disputes

Competition Counseling and Compliance

EDUCATION

- Dr. iur., University of Mannheim
- 2. State Exam, District Court Mannheim
- 1. State Exam, University of Heidelberg

BAR ADMISSIONS

Rechtsanwalt, Germany

PUBLICATIONS

Vertriebsfranchising im europäischen Kartellrecht (Distributive franchising in European antitrust law), FIW publication series (volume 205) of Forschungsinstituts für Wirtschaftsverfassung und Wettbewerb e.V., Cologne, C. Heymanns Verlag, 2005

Co-author, „Bildung von Bietergemeinschaften durch konkurrierende Unternehmen“ (Formation of bidding consortia by competing companies), NZBau 2012, 213

Co-author, „Amtshaftung in der deutschen Fusionskontrolle – Möglichkeiten und Grenzen aus gemeinschaftsrechtlicher Perspektive“ (Official liability in

German merger control – possibilities and limits from a community law perspective), WuW 2013, 126

Co-author, „Ist die patentrechtliche Unzulässigkeit Voraussetzung für den kartellrechtlich verbotenen Missbrauch von Patentverfahren bei Arzneimitteln? – Zur Pfizer-Entscheidung des Italienischen Consiglio di Stato im Kontext der AstraZeneca-Rechtsprechung des EuGH (Is inadmissibility under patent law a prerequisite for the abuse of patent procedures for drugs prohibited by antitrust law? – On the Pfizer decision of the Italian Consiglio di Stato in the context of the AstraZeneca case law of the ECJ)“, Der IP Rechtsberater, 2014, 140

Chapter „Antitrust Law Compliance“, in: Stober/Ohrtmann: Compliance – Handbuch für die öffentliche Verwaltung, Kohlhammer, 2015

PRESENTATIONS & SPEECHES

Speaker, EUROFORUM Jahrestagung Zusatzversorgung, Berlin, 4/5 November 2014, 13/14 June 2016, 2 July 2019, Speeches on various antitrust law issues within the framework of supplementary pensions in the public sector (Versorgungsanstalt des Bundes und der Länder - VBL), in particular on the effects of the countervalue decisions of the BGH.